{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    8,
    29
  ],
  "modelUsed": "gemini-3-flash-preview",
  "advanced": {
    "studyAmendments": [
      {
        "id": "amend_1",
        "number": "a",
        "name": "Amendment a",
        "scope": {
          "id": "2a1ca07c-9b7d-4a3b-81a1-0b9654e0b09f",
          "code": "Global",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Global",
          "instanceType": "Code"
        },
        "primaryReason": {
          "id": "877472c7-71c7-492e-8ef9-fdaf25d16ddb",
          "code": {
            "id": "4ccfa068-d6b3-4ebf-80ed-8c2a73790a39",
            "code": "C98782",
            "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
            "codeSystemVersion": "25.01d",
            "decode": "Protocol Amendment",
            "instanceType": "Code"
          },
          "otherReason": "Protocol Amendment",
          "instanceType": "StudyAmendmentReason"
        },
        "geographicScopes": [
          {
            "id": "c92a49c0-4453-489d-bbba-8c18539e3b17",
            "type": {
              "id": "4eaf611c-a4ff-4021-b815-cdaf40cebd07",
              "code": "Global",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Global",
              "instanceType": "Code"
            },
            "instanceType": "GeographicScope"
          }
        ],
        "instanceType": "StudyAmendment",
        "summary": "Amendment (a) was electronically signed and approved by Lilly on 28 Sep 2018.",
        "effectiveDate": "2018-09-28",
        "reasonIds": [
          "ar_1_1"
        ],
        "previousVersion": "Original Protocol",
        "newVersion": "a"
      },
      {
        "id": "amend_2",
        "number": "b",
        "name": "Amendment b",
        "scope": {
          "id": "20bc9589-1197-4869-9f8f-71c6197861d7",
          "code": "Global",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Global",
          "instanceType": "Code"
        },
        "primaryReason": {
          "id": "a4122d2e-a660-4539-8b31-8c118f6cd2c2",
          "code": {
            "id": "a0756ed2-8739-4f77-86ce-6da552935c8b",
            "code": "C98782",
            "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
            "codeSystemVersion": "25.01d",
            "decode": "Protocol Amendment",
            "instanceType": "Code"
          },
          "otherReason": "Protocol Amendment",
          "instanceType": "StudyAmendmentReason"
        },
        "geographicScopes": [
          {
            "id": "93aac893-885d-4642-a4ab-16d7e64673fa",
            "type": {
              "id": "725febcf-00df-471a-920d-99f5117d1715",
              "code": "Global",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Global",
              "instanceType": "Code"
            },
            "instanceType": "GeographicScope"
          }
        ],
        "instanceType": "StudyAmendment",
        "summary": "The main reason for preparation of this amendment was to incorporate changes to study procedures due to the COVID-19 pandemic, as detailed in Appendix 8, and to update the protocol for the SURPASS-4 study.",
        "effectiveDate": "2020-07-10",
        "reasonIds": [
          "ar_2_1",
          "ar_2_2"
        ],
        "previousVersion": "a",
        "newVersion": "b"
      }
    ],
    "amendmentReasons": [
      {
        "id": "ar_1_1",
        "code": "ADMINISTRATIVE",
        "description": "Administrative",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_2_1",
        "code": "REGULATORY",
        "description": "Regulatory",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_2_2",
        "code": "OPERATIONAL",
        "description": "Operational",
        "instanceType": "AmendmentReason"
      }
    ],
    "countries": [
      {
        "id": "country_1",
        "name": "United States",
        "instanceType": "Country",
        "code": "US"
      }
    ],
    "studySites": [],
    "summary": {
      "amendmentCount": 2,
      "countryCount": 1,
      "siteCount": 0
    },
    "geographicScope": {
      "id": "geo_1",
      "name": "Study Geographic Scope",
      "scopeType": "Global",
      "instanceType": "GeographicScope",
      "countryIds": [
        "country_1"
      ],
      "regions": [
        "North America"
      ]
    }
  },
  "rawResponse": {
    "amendments": [
      {
        "number": "Original Protocol",
        "effectiveDate": "2018-07-18",
        "summary": "Initial protocol for the efficacy and safety study of LY3298176 once weekly versus insulin glargine in patients with type 2 diabetes and increased cardiovascular risk (SURPASS-4).",
        "previousVersion": null,
        "newVersion": "Original",
        "reasons": [
          "Scientific"
        ]
      },
      {
        "number": "a",
        "effectiveDate": "2018-09-28",
        "summary": "Amendment (a) was electronically signed and approved by Lilly on 28 Sep 2018.",
        "previousVersion": "Original Protocol",
        "newVersion": "a",
        "reasons": [
          "Administrative"
        ]
      },
      {
        "number": "b",
        "effectiveDate": "2020-07-10",
        "summary": "The main reason for preparation of this amendment was to incorporate changes to study procedures due to the COVID-19 pandemic, as detailed in Appendix 8, and to update the protocol for the SURPASS-4 study.",
        "previousVersion": "a",
        "newVersion": "b",
        "reasons": [
          "Regulatory",
          "Operational"
        ]
      }
    ],
    "geographicScope": {
      "type": "Global",
      "countries": [
        {
          "name": "United States",
          "code": "US"
        }
      ],
      "regions": [
        "North America"
      ],
      "plannedSites": null
    },
    "sites": []
  }
}